Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Triple Negative Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Breast Cancer (2426
)
HER2 Negative Breast Cancer (538
)
HER2 Positive Breast Cancer (509
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
Breast Cancer (2426
)
HER2 Negative Breast Cancer (538
)
HER2 Positive Breast Cancer (509
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
›
Associations
(362)
News
Trials
Search handles
@ABhealer108
@ADesaiMD
@AndreaLMerrill
@Baricorcho
@BianchiniGP
@BollamRajesh4
@CarmenCalfa
@CarmenCriscit
@CharuAggarwalMD
@DrAttai
@DrChoueiri
@DrFaridSaleh
@DrFelipeAdes
@DrGattiMays
@DrHBurstein
@DrJuneJD
@DrLauraEsserman
@DrMedOnco
@DrMirallas
@DrRBarroso
@DrSGraff
@DrVMisra
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@E_de_Azambuja
@ErikaHamilton9
@ErinGillespieMD
@FAndreMD
@FernandoOnco
@FrancescoSche20
@FunchainMD
@GeorgeSledge51
@GlopesMd
@IsabelP12002691
@JAMouabbi
@JYangMDPhD
@JavierCortesMD
@KariWisinski_MD
@KefahMokbel
@Latinamd
@Liz_ORiordan
@LoiSher
@LujanPomponio
@MCristofanill
@MVanMeterMD
@MeiWeiOncology
@MridulaGeorgeMD
@MyriamChalabi
@Nader_Guilherme
@NagiSaghir
@NeelamDesai_MD
@NicoleKuderer
@OmidHamidMD
@OncoThor
@PTarantinoMD
@RandySweisMD
@RenoHemonc
@RitaNandaMD
@RobClarkeLab
@RodriguezGIMD
@SKabrajiMD
@SidYadavMD
@StephenVLiu
@StoverLab
@SuyogCancer
@SyedMAhmedMDPhD
@VivekSubbiah
@abhenilmittal
@aftimosp
@angela_toss
@antgiorda
@antoniomarraMD
@antonyruggeri
@benjiwal
@bin_abeid
@bpellegrino89
@cdanicas
@changjeesuk1
@curijoey
@darioT_
@dawood_findakly
@dr_yakupergun
@dradityabardia
@drallysonocean
@drsarahsam
@drteplinsky
@drvineetgovinda
@fredhow
@gandhi_shipra
@hmcarthur
@hoperugo
@ilyassahinMD
@itsnot_pink
@jamecancerdoc
@jasonlukemd
@jesusanampa
@jrgralow
@jryckman3
@kevinpunie
@kristinrojasmd
@mabelonc
@maryam_lustberg
@melindatelli
@naborala
@navstruck
@ndenduluri1
@nlinmd
@ogarrieta
@oncologician
@oreganruth
@pradeepbab
@prat_aleix
@rbryanbell
@renata_bonadio
@rleonferre
@saadvikdr
@siddharthkunte
@stolaney1
@subatomicdoc
@teamoncology
@tmprowell
@todrashish
@tumastologo1
@weldeiry
@weoncologists
@z_veitch
Search handles
@ABhealer108
@ADesaiMD
@AndreaLMerrill
@Baricorcho
@BianchiniGP
@BollamRajesh4
@CarmenCalfa
@CarmenCriscit
@CharuAggarwalMD
@DrAttai
@DrChoueiri
@DrFaridSaleh
@DrFelipeAdes
@DrGattiMays
@DrHBurstein
@DrJuneJD
@DrLauraEsserman
@DrMedOnco
@DrMirallas
@DrRBarroso
@DrSGraff
@DrVMisra
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@E_de_Azambuja
@ErikaHamilton9
@ErinGillespieMD
@FAndreMD
@FernandoOnco
@FrancescoSche20
@FunchainMD
@GeorgeSledge51
@GlopesMd
@IsabelP12002691
@JAMouabbi
@JYangMDPhD
@JavierCortesMD
@KariWisinski_MD
@KefahMokbel
@Latinamd
@Liz_ORiordan
@LoiSher
@LujanPomponio
@MCristofanill
@MVanMeterMD
@MeiWeiOncology
@MridulaGeorgeMD
@MyriamChalabi
@Nader_Guilherme
@NagiSaghir
@NeelamDesai_MD
@NicoleKuderer
@OmidHamidMD
@OncoThor
@PTarantinoMD
@RandySweisMD
@RenoHemonc
@RitaNandaMD
@RobClarkeLab
@RodriguezGIMD
@SKabrajiMD
@SidYadavMD
@StephenVLiu
@StoverLab
@SuyogCancer
@SyedMAhmedMDPhD
@VivekSubbiah
@abhenilmittal
@aftimosp
@angela_toss
@antgiorda
@antoniomarraMD
@antonyruggeri
@benjiwal
@bin_abeid
@bpellegrino89
@cdanicas
@changjeesuk1
@curijoey
@darioT_
@dawood_findakly
@dr_yakupergun
@dradityabardia
@drallysonocean
@drsarahsam
@drteplinsky
@drvineetgovinda
@fredhow
@gandhi_shipra
@hmcarthur
@hoperugo
@ilyassahinMD
@itsnot_pink
@jamecancerdoc
@jasonlukemd
@jesusanampa
@jrgralow
@jryckman3
@kevinpunie
@kristinrojasmd
@mabelonc
@maryam_lustberg
@melindatelli
@naborala
@navstruck
@ndenduluri1
@nlinmd
@ogarrieta
@oncologician
@oreganruth
@pradeepbab
@prat_aleix
@rbryanbell
@renata_bonadio
@rleonferre
@saadvikdr
@siddharthkunte
@stolaney1
@subatomicdoc
@teamoncology
@tmprowell
@todrashish
@tumastologo1
@weldeiry
@weoncologists
@z_veitch
Filter by
Latest
8ms
#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME eval🔗 https://t.co/RrSAUicpxp 👉🏽ALL CME 🔗 https://t.co/XMu7LDS9CP 🤔@maryam_lustberg @adrianakahnmd taught us early stage TNBC + autoimmune dz, test your 🧠 🧐What neoadj tx? 36yo👩🏼 T2N1 TNBC wild-type germ BRCA #Crohns: IFX/AZA (@AdrianaKahnMD)
8 months ago
BRCA (Breast cancer early onset)
8ms
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? - @PTarantinoMD #Cancer #OncoDaily #Oncology #PaoloTarantino #research https://t.co/KCAx079Xbc (@oncodaily)
8 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
8ms
Very interesting and can't wait to hear more: 👉🏻We know that in HR+ (unlike in TNBC and HER2+) that not archiving a pCR does not always translate in poorer outcomes and so it is really inportant to analyze the EFS data in both the IO and SOC groups before making any definitive… https://t.co/XTSj46bknJ (@JAMouabbi)
8 months ago
HER-2 (Human epidermal growth factor receptor 2)
8ms
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? Which one should be utilized first? Find the answer in our latest letter to the editor, now published on @Annals_Oncology. @curijoey @stolaney1 https://t.co/KqE0aC8FcL (@PTarantinoMD)
8 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
9ms
Read about the just published ESTIMATE triple-negative tool, which helps estimate mortality in women with triple-negative breast cancer. The tool quantifies risks of #BCSM, non-BCSM, and all-cause mortality. @stolaney1 @DrRFreedman @nlinmd @NabihahTayob https://t.co/vfFpAaFRiE (@DFCI_BreastOnc)
9 months ago
9ms
Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in HR-positive breast cancer, the future of ADCs in TNBC, and the importance of a shared decision-making process in breast cancer treatment. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/eAR3QZt7Pa (@OncLive)
9 months ago
HR positive
9ms
Thanks @AnwaarSaeed3 for the opportunity to speak on #tnbc novel therapies at the Pittsburgh Annual Oncology Symposium. @teekayowo (@KariWisinski_MD)
9 months ago
9ms
And onwards to HER-2+ and triple negative breast cancer. Stellar review by @rleonferre. I feel ready for my board review when it comes to this topic. If you missed out on the 2023 Mayo Clinic Oncology review course, we will be back next year. (@OncoThor)
9 months ago
Review
|
HER-2 (Human epidermal growth factor receptor 2)
9ms
Thank you for joining us at the 2023 COEDS Dinner Series TNBC with our COEDS Chair, @DrReshmaMahtani Chief of Breast Medical Oncology at Miami Cancer Institute, @BaptistHealthSF ❤️ See upcoming COEDS dinner programs South Florida at https://t.co/MZ6P93lMJV. (@TotalHealthConf)
9 months ago
9ms
@gotoPER IBC East day 1 is here! Opening lecture on treatment tailoring for TNBC by @FilipaLynce, followed by many highly awaited talks. Excited to connect with great experts and friends! (@PTarantinoMD)
9 months ago
9ms
6/6 #TumorBoardTuesday Thurs Case🎀 👍Emerging data re: new neoadjuvant approaches in localized #TNBC (SG not yet approved) 🤔What role will ctDNA play in future adj tx discussions? 📅Save the date for 07.18: @brian_rini @katy_beckermann tackle continuing IO in refractory #RCC (@JohnEbbenMDPhD)
9 months ago
Clinical • Circulating tumor DNA
9ms
4/6 #TumorBoardTuesday Thurs Case🎀 🎥 TBT in a video: @ArielleMedford talks about the future of therapy in stage II/III #TNBC-- Use of MRD monitoring and 🩸🧬ctDNA to guide therapy escalation/de-escalation More targeted therapies in neoadjuvant setting (ADCs). (@JohnEbbenMDPhD)
9 months ago
Clinical • Video • Circulating tumor DNA
9ms
3/6 #TumorBoardTuesday Thurs Case🎀 🎥 TBT in a video: @ArielleMedford talks about her approach to treating localized #TNBC. Neoadjuvant tx is SOC w several advantages: ✅Improve surgical margins/downstage ✅Learn about tumor biology and adapt therapy in the adjuvant setting (@JohnEbbenMDPhD)
9 months ago
Clinical • Video
9ms
5/6 #TumorBoardTuesday Thurs Case🎀 📷 TBT in an image: Treatment of stage II/III TNBC involves pt centered discussion. Check out a suggested treatment algorithm, data from phase II NeoSTAR trial (SG as neoadjuvant tx) & new trial design evaluating addition of IO & SG. (@JohnEbbenMDPhD)
9 months ago
Clinical • P2 data
9ms
2/6 #TumorBoardTuesday Thurs Case🎀 Take🏠msgs: In #TNBC: ✅ Neoadj chemoIO is standard in localized TNBC (stage II/III) ✅ Emerging data re: ADCs (SG) in neoadjuvant tx ✅ Remember NGS and germline NGS! 📚Here’s @dradityabardia @ArielleMedford’s thread: https://t.co/SyR2NqMMRR (@JohnEbbenMDPhD)
9 months ago
Clinical • Next-generation sequencing
9ms
Check out Dr. Sara Tolaney @stolaney1 @DFCI_BreastOnc discussing Management of TNBC #breastcancer #TNBC @i3health https://t.co/Ranl1WjPqW (@Sameh_VuMedi)
9 months ago
9ms
Thank you🙏🏼 for an outstanding & invaluable session on the effectiveness of Trop2-targeted ADCs in TNBC during #TumorBoardTuesday! Stay tuned for the Case Wrap Up 🎀 on 07/13/23 📅Save the date for 07.18, when @brian_rini @katy_beckermann tackle continuing IO in refractory #RCC (@TumorBoardTues)
9 months ago
9ms
Excited to share the latest from Margarite Matossian! "Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities" #tnbc #bcsm @RitaNandaMD @MsNanchen https://t.co/50XtPAazjz (@UChicagoBreast)
9 months ago
9ms
14/15 #TumorBoardTuesday 💥New💥ways of assessing high risk localized disease? 🔍Increasing sensitive ctDNA assays allow detection of molecular residual disease (MRD) after surgery 🔎+MRD = high risk of recurrence. ✨ASPRIA phase 2 of SG + atezolizumab in pts with TNBC and +MRD (@ArielleMedford)
9 months ago
Clinical • P2 data • Surgery • Circulating tumor DNA
|
Tecentriq (atezolizumab)
9ms
10/15 #TumorBoardTuesday #BCSM ✨TROPION-PanTumor01✨ DatoDXd in 43 patients with mTNBC ➡️Prelim: 39% ORR, 84% disease control, manageable safety 📚#IanKrop https://t.co/ROeHwbzFlm (@ArielleMedford)
9 months ago
Clinical • Pan tumor
9ms
12/15 #TumorBoardTuesday #BCSM 📌Other ADCs target Trop2 ✨BEGONIA✨ DatoDXd + durvalumab in 29 pts w/mTNBC ➡️74% response - 7% complete, 67% partial 📚#PeterSchmid https://t.co/hLYGlnh4CT (@ArielleMedford)
9 months ago
Clinical
|
Imfinzi (durvalumab)
9ms
#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME eval🔗 https://t.co/AERuZ52USg 👉🏽ALL CME 🔗 https://t.co/6lPEs7cS4r 🤔@dradityabardia @ArielleMedford taught us Trop2-targeted ADCs in TNBC, test your 🧠with Q 🧐What tx would you pick? 62yo 👩🏽🦳 newly-dx TNBC (T2N0) negative germline test (@ArielleMedford)
9 months ago
9ms
11/15 #TumorBoardTuesday ✨TROPION-Breast02✨ DatoDXd in 44 patients with mTNBC ➡️34% ORR, manageable safety 📚#RebeccaDent https://t.co/dGejX3x04N (@ArielleMedford)
9 months ago
Clinical
9ms
13/15 #TumorBoardTuesday What about DatoDXd in localized TNBC? ✨TROPION-Breast03 Phase 3 Dato-DXd +/- durvalumab in pts with residual TNBC after neoadj Rx ➡️Control: capecitabine +/- pembrolizumab 🔮Looking forward to results comparing adj ADCs to SOC! 📚https://t.co/lmZxMfMj03 (@ArielleMedford)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Imfinzi (durvalumab) • capecitabine • datopotamab deruxtecan (DS-1062a)
9ms
8/15 #TumorBoardTuesday 📌What about adjuvant SG? Studies ongoing ✨ASCENT-05/OptimICE-RD (AFT-65) 📍randomized Phase 3 📍adj SG + pembro vs pembro +/- cape in pt with TNBC & residual dz after surgery✂️ cT1-T3 (any N) 🏁Primary endpoint IDFS 📚@stolaney1 https://t.co/3rJYiZke5I (@ArielleMedford)
9 months ago
Clinical • Surgery
|
Keytruda (pembrolizumab)
9ms
5/15 #TumorBoardTuesday 👨🏽🏫Mini tweetorial 3👩🏼🏫 📌Sacituzumab govitecan (SG) 🔹first ADC approved for use in TNBC! 🫧2022: ADC T-DXd approved for HER2-low BC, including TNBC ⚠️Currently, SG approved ONLY in metastatic BC 👨🏽🔬Ongoing studies evaluating in localized TNBC (NeoSTAR🌟) (@ArielleMedford)
9 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy)
9ms
6/15 #TumorBoardTuesday #BCSM 👨🏽🏫Mini tweetorial 4👩🏼🏫 ✨NeoSTAR✨ ✅Phase 2 assessed neoadj SG in T1c-T4 (any N) TNBC ✅Response-guided design. ✅After 4 cycles SG, if bx showed no pCR, pt could receive added neoadj Rx of MD choice 🏁Primary objective = pCR rate (@ArielleMedford)
9 months ago
P2 data
9ms
4/15 #TumorBoardTuesday #BreastCancer 👨🏽🏫Mini tweetorial 2👩🏼🏫 📌Sacituzumab govitecan (SG) 🔹approved by the @US_FDA for >2L in metastatic TNBC in 2020 based on landmark ASCENT trial ‼️‼️Approval does 🙅🏼♀️ NOT require testing for Trop2‼️‼️ 📚#SaraHurvitz https://t.co/J2nIIy2oeg (@ArielleMedford)
9 months ago
Metastases
|
Trodelvy (sacituzumab govitecan-hziy)
9ms
🏝️Are Trop2-targeted ADCs effective in the metastatic #BreastCancer setting & beyond? 🍹Tell a friend & join @dradityabardia @ArielleMedford HERE on #TumorBoardTuesday Tues 07/11/23 at 8pm ET for the latest! 🌴Earn CME! https://t.co/Gzqzvik9BR #BCSM #TNBC (@TumorBoardTues)
9 months ago
Metastases
9ms
You're invited! Listen to the podcast of @stolaney1 sharing a preview of this week's #webinar "Expert Perspectives in the Management of Triple-Negative #BreastCancer" And remember to sign up for this exciting #live event now @ https://t.co/AOmdoLFOSz #CME https://t.co/fdRo1Oq0we (@OncData)
9 months ago
CME
9ms
Day 2 and last day of the @btfoundation conference. With Dr. Kai Sun and @AkshjotP Two phenomenal speakers in the breast cancer arena. Is #TNBCOLOGIST a word? @EthanBurns_MD @JennyCChang1 @RaviPingali1 (@bmtdoc63)
9 months ago
9ms
Happening now. Dr. Kai Sun of #HMNCC @HMethodistMD @MethodistHosp presenting @btfoundation Updates in HemeOnc 2023. #TNBC Fantastic line of speakers and great talks. @EthanBurns_MD @AkshjotP @RaviPingali1 @JennyCChang1 @VivekSubbiah @binayshah (@bmtdoc63)
9 months ago
9ms
Ive had a case like this that turned out to be Breast Lymphoma. I always insist the pathologist puts some ihc confirming breast ca origin (gata3/sox10 etc) esp in tnbc. Another turned out to be egfr+ nsclc (lump was in axillary tail where she prev had ICD for effusion) (@shaunak_3)
9 months ago
EGFR (Epidermal growth factor receptor) • SOX10 (SRY-Box 10) • GATA3 (GATA binding protein 3)
9ms
Immunotherapy 1 Colorectal .... for msi -h metastatic disease 2 NSCLC ..... PD receptor > 1 % 3 gastric ca ..... MMR deficient metastatic disease 4 breast ca ..... adjuvant for TNBC Additional targets includes types of EGFR receptors ( I.e HER2) (@Amanu3536)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
9ms
You're invited! Don't miss this interview in which @stolaney1 shares a preview of next week's live #webinar "Expert Perspectives in the Management of Triple-Negative #BreastCancer." Don't forget to sign up before July 12 @ https://t.co/zP2MUUf0QR #CME https://t.co/F6bI5JZ9AI (@OncData)
9 months ago
Interview
9ms
Real-world study of early relapsed #TNBC. “Women with early relapsed metastatic TNBC … a highly unmet medical need.” https://t.co/iTH46M6Hea 🎯 Commentary by @DrReshmaMahtani: https://t.co/M8ApYBj8Ms #bcsm #mTNBC (@JaniceTNBCmets)
9 months ago
Clinical • Real-world evidence • Real-world • Metastases
9ms
Very cool ! If you ever repeat such analyses it would be very interesting to see how MYC and its co-amplified ubiquitin ligase UBR5 would profile relative to priming status. Especially related to their heterogeneity in TNBC tissues (Fig. 6A,B in https://t.co/dVSCC4vwBi) (@westermarcklab)
9 months ago
UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
9ms
How to Treat Small Triple Negative Breast Cancer: Priyanka Sharma and Alexandra Thomas will address this topic in a Clinical Controversies session at #SABCS23 (December 7), moderated by @DrLisaCarey. Learn more: https://t.co/MUdvf5efw8 @A_THOMASMD (@SABCSSanAntonio)
9 months ago
Clinical
9ms
Promising results of Providence-sponsored trial from @davidbpage & colleagues published in @Nature_NPJ Breast Cancer. Trial evaluated pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients w/ metastatic #TNBC. Details: https://t.co/hF3DFdWDax. (@ChilesResearch)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • paclitaxel • capecitabine
9ms
Listen as @awolff & @StoverLab discuss the latest advancements in chemotherapy de-escalation for patients with HER2+ and triple negative #breastcancer. Click here to be the first to know about the latest Breast Cancer Breakthroughs: https://t.co/rICYSeo67X (@SusanGKomen)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
9ms
Honored to be part of this amazingly talented team!!! @ChilesResearch @UTSWNews @CedarsSinai @davidbpage @WalterUrba @hmcarthur and more. New insights into #Immunotherapy #biomarkers #clinicaltrials for #TNBC. doi: 10.1038/s41523-023-00541-2 (@WWredmond4)
9 months ago
Clinical • IO biomarker
9ms
Targeting AR in triple negative breast cancer has been challenging, but as our understanding of biology improves, opportunities for biomarker-driven and combination approaches may yet be fruitful👇@KariWisinski_MD and @oreganruth (@marina_sharifi)
9 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login